Hi Maximillian, you may find these references helpful:

http://www.ncbi.nlm.nih.gov/pubmed/17453603

http://www.ncbi.nlm.nih.gov/pubmed/24093525

This is another good question that we have very little empirical evidence to base an answer on due to the prohibition on cannabis use and research on its potential therapeutic effects for the past 50-70 years in the US. Finally, there is a big change in policy both at NIH and at the State level, with NIDA willing to grow much more "legal cannabis" through its contract with U Miss, specifically for therapeutic trials in the US, and with many States funding their own therapeutic research which will be able to use cannabis that is produced, analyzed and provided by licenses cultivation centers in their states and the dispensaries where registered patients obtain their cannabinoid medicine. IL is one of the newest states and is initiating a "closed loop" system where all MC will be provided by licensed growers, have extensive laboratory testing for safety and composition of active ingredients, and dispensaries will have to keep records of all their customers and the amounts of specific products bought/consumed. By combining such a closed system with a standardized and centralized data reporting system at each level and interaction between a patient and their dispensary and their primary healthcare provider, we will be able to gain longitudinal observational answers to questions like this and perhaps even say what particular strains or phenotypes work best in specific disorders. Please see my description of the proposed Community-Based, Patient-centered IL Clinical Cannabis Research Network (IL CBCCRN) either on my linkedIn profile or my Website, www.DavidOstrowConsulting.com

www.DavidOstrowConsulting.com

By the way, in Germany ADHD is in the TOP 5 diagnoses refer to permissions to buy medical marijuana